Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-02-25

FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for liraglutide (NDA 022341).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Liraglutide (generic) (liraglutide)

Snippet

SUPPL AP for LIRAGLUTIDE (LIRAGLUTIDE)